Calico

Learn more about our story: calicolabs.com/story/our-stor…

Today, that foundation supports our progress from discovery into clinical- and early-stage programs across multiple age-related diseases. We continue to build on our original vision, working to translate insights into potential therapies that may improve healthspan.

From the beginning, we took on a challenge that still defines our work today: how to better understand the biology of aging and its role in disease.

@PKDFoundation Calico's ADPKD program is investigational. No treatment based on this research has been approved by the FDA or other governmental agency and its safety and effectiveness have not been established. (5/5) #ADPKD

@PKDFoundation Learn more about how we’re advancing clinical research in ADPKD and our ongoing global Phase 2 trial: calicolabs.com/clinical-trial… (4/5)

We recently joined the @PKDFoundation community at PKDCon, which brought together people living with ADPKD, their caregivers, and family members; and the PKD Centers of Excellence, a conference for nephrologists and investigators focused on advancing standards of care. (1/5)

Learn more in the Calico Story: calicolabs.com/story/expandin… (5/5)

As David explains, “For anyone who wants to apply these models to their own data, everything is there. The goal is not just to build better models, but to make them usable so more scientists can ask better questions of their data.” (4/5)

Genomic deep learning models have significant potential to advance how scientists study DNA and RNA, but computing demands have kept many of these tools out of reach for researchers who could benefit from them. (1/5)

Recently published in Nature, Calico scientists collaborated on new NIH research that advances understanding of immune regulation and how regulatory cells help control tissue inflammation. Read the paper: nature.com/articles/s4158…

Fosigotifator is an investigational drug. Its safety and efficacy have not been established and it has not been approved by any regulatory authority. (7/7) Learn more: calicolabs.com/press/calico-l…

Fosigotifator was previously selected for the FDA’s START program, an initiative focused on accelerating the development of novel treatments for rare diseases. (6/7)

We’re pleased to announce the FDA has granted Breakthrough Therapy Designation to fosigotifator, Calico’s investigational treatment for Vanishing White Matter (VWM) disease. (1/7)